Welcome to our dedicated page for CytomX Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics stock.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a leading oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics with its proprietary Probody® technology platform. Based in South San Francisco, CytomX leverages this platform to develop cancer immunotherapies that target clinically-validated and novel oncological targets. The unique Probody® therapeutics are designed to enhance the tumor-targeting capabilities of antibodies while minimizing toxicity in healthy tissues.
Probody® therapeutics operate by taking advantage of the unique conditions present in the tumor microenvironment, thereby improving both the efficacy and safety profiles of monoclonal antibody treatments, including cancer immunotherapies, antibody-drug conjugates (ADCs), and T-cell-recruiting bispecific antibodies. The company's innovative pipeline includes several promising candidates currently in various stages of development.
Among its recent achievements, CytomX is advancing its lead programs, CX-2051 and CX-801, into Phase 1 clinical studies. CX-2051 is an ADC that targets EpCAM-expressing tumors, including colorectal cancer, while CX-801 aims to overcome limitations associated with interferon-directed therapies. These candidates exemplify the versatility and productivity of CytomX's Probody® platform, promising significant advancements in cancer treatment.
CytomX has established strategic collaborations with industry leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to further enhance its research and development capabilities. As a result, the company is well-positioned to lead in the development of conditionally activated biologics designed for localized action within tumor microenvironments.
Financially, CytomX has made significant strides in cost control and strategic allocation of capital towards lead pipeline programs. In 2023, the company reduced its total operating expenses by $46.8 million, driven by workforce reductions and strategic pipeline prioritization. Research and development expenses decreased by $34.0 million, while general and administrative expenses decreased by $12.8 million.
For more information about CytomX and its innovative approach to cancer treatment, visit their official website at www.cytomx.com and follow them on LinkedIn and Twitter.
CytomX Therapeutics (NASDAQ: CTMX) and Moderna (NASDAQ: MRNA) have announced a collaboration to create mRNA-based therapeutics using CytomX's Probody® platform. CytomX will receive $35 million upfront, including $5 million for research funding, with potential future payments of up to $1.2 billion in development milestones and royalties on commercialized products. The partnership aims to develop conditionally activated therapies for various diseases, enhancing both companies' therapeutic pipelines.
CytomX Therapeutics (Nasdaq: CTMX) announced plans to share its 2023 pipeline priorities and provide a data update for the CX-2029 Phase 2 cohort expansion study on January 5, 2023. The updates will follow a conference call at 5:00 p.m. ET. CytomX, a clinical-stage oncology biopharmaceutical company, focuses on developing conditionally activated treatments through its Probody® technology. Its pipeline includes ADCs and T-cell engaging bispecific antibodies, with CX-2029 currently in development, showing promise for patients with squamous non-small cell lung cancer.
CytomX Therapeutics (Nasdaq: CTMX) will have its CEO, Sean McCarthy, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. ET. Attendees can watch a live webcast on CytomX's website, and an archived replay will be available for 30 days post-event. The company specializes in conditionally activated oncology therapeutics and has a diverse pipeline including investigational therapies like CX-2029 and collaborations with AbbVie and Amgen. For further details, visit www.cytomx.com.
CytomX Therapeutics (CTMX) announced that Phase 2 data for CX-2009, an ADC targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8, 2022. The data focuses on praluzatamab ravtansine for advanced HR+/HER2- breast cancer and triple-negative breast cancer. Despite previous decisions not to advance the program without a partner, the research has provided valuable insights for future Probody therapeutic candidates. The poster session is scheduled for 7:00 am - 8:15 am CT, featuring Dr. Kathy Miller as the presenting author.
CytomX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop bispecific cancer therapies leveraging CytomX's Probody® platform and Regeneron's Veloci-Bi® technology. CytomX will receive a $30 million upfront payment and could earn up to $2 billion in future milestone payments related to research and commercialization. The partnership aims to create conditionally activated therapies designed to minimize off-target effects, potentially benefiting tumor types unresponsive to current immunotherapy approaches.
Regeneron Pharmaceuticals and CytomX Therapeutics have entered a significant collaboration to develop next-generation bispecific immunotherapies. CytomX will receive an upfront payment of $30 million and could earn up to $2 billion in future milestones. The collaboration focuses on utilizing CytomX's Probody® technology and Regeneron's Veloci-Bi® platform to create therapies that activate specifically in tumor environments, potentially improving treatment efficacy and reducing side effects. The partnership aims to expand cancer treatment options significantly.
CytomX Therapeutics (CTMX) reported its Q3 2022 financial results and business updates, highlighting advancements in its oncology pipeline. The company is progressing on CX-2051 and CX-801, both slated for IND submissions in 2023. CX-904 is currently in Phase 1, while collaborations with Bristol Myers Squibb on BMS-986249 and AbbVie on CX-2029 continue in Phase 2. Financially, cash reserves decreased to $194.3 million from $305.2 million year-over-year, with revenue of $16.9 million. R&D expenses rose to $30.4 million, reflecting restructuring expenses.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming presentation of preclinical data for CX-801, a masked interferon alpha-2b therapeutic candidate, at the SITC Annual Meeting in Boston. CX-801 aims to improve tolerability and efficacy in treating tumors by leveraging a favorable therapeutic index. The company plans to file an IND for CX-801 in the second half of 2023, with ongoing exploration of its potential in both responsive and non-responsive tumor types. The presentation is scheduled for November 10-11, 2022, detailing the benefits of CX-801 combined with PD-L1 blockade.
CytomX Therapeutics (Nasdaq: CTMX) has announced participation in two key investor conferences in November. CEO Sean McCarthy will engage in a virtual fireside chat for the BMO Biopharma Spotlight Series: Oncology Day on November 9 at 11:30 a.m. ET, followed by a session at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 8:30 a.m. ET in New York. A live webcast will be available on CytomX’s website, where management will also hold one-on-one investor meetings.
CytomX Therapeutics (CTMX) will announce its third quarter 2022 financial results on November 8, 2022, after market close. Following the results, a conference call will be hosted at 5:00 p.m. ET to discuss the findings and provide updates. The company focuses on conditionally activated oncology therapeutics, with a pipeline including seven therapeutic candidates such as CX-2029 and Probody therapeutics partnered with leading biopharmaceutical companies. For further details, visit CytomX's website.
FAQ
What is the current stock price of CytomX Therapeutics (CTMX)?
What is the market cap of CytomX Therapeutics (CTMX)?
What is CytomX Therapeutics, Inc.?
What is the Probody® technology platform?
Which are the leading programs of CytomX?
Who are CytomX's strategic partners?
What recent financial achievements has CytomX made?
What are the benefits of Probody® therapeutics?
How does CytomX's Probody® platform contribute to cancer treatment?
Where is CytomX Therapeutics located?
What types of cancer does CX-2051 target?
How can I learn more about CytomX's latest developments?
